BioCentury | Feb 18, 2016
Financial News

Corvidia raises $26M, licenses cardio candidate

...hopes to have results about a year after the trial starts. Davidson was CMO of Omthera Pharmaceuticals Inc....
BioCentury | May 19, 2014
Company News

Ligand, AstraZeneca deal

...Ligand partnered with AstraZeneca's Omthera Pharmaceuticals Inc. subsidiary to develop products to treat dyslipidemia, including hypertriglyceridemia. The products...
...for milestone payments of up to $44.5 million, as well as tiered, mid-to-high, single-digit royalties. Omthera...
...molecule into an inactive prodrug to be activated by enzymes in the liver. AZ acquired Omthera...
BioCentury | May 12, 2014
Strategy

Build up to break up

...guidance in last week's review. AZ gained the product in its July 2013 acquisition of Omthera Pharmaceuticals Inc....
BioCentury | May 12, 2014
Clinical News

Epanova regulatory update

...AZ gained the product through its July acquisition of Omthera Pharmaceuticals Inc. (see BioCentury, July 22, 2013). Omthera...
BioCentury | May 7, 2014
Company News

FDA approves AZ's Epanova for severe hypertriglyceridemia

...has not yet set a price. AZ gained Epanova through its acquisition last year of Omthera Pharmaceuticals Inc....
BioCentury | Mar 24, 2014
Company News

Novira management update

...Radnor, Pa. Business: Infectious Hired: Christian Schade as CEO, formerly EVP and CFO of Omthera Pharmaceuticals Inc....
BioCentury | Sep 23, 2013
Clinical News

Epanova regulatory update

...DHA). AstraZeneca gained the product through its July acquisition of Omthera Pharmaceuticals Inc. (see BioCentury, July 22). Omthera...
BioCentury | Sep 19, 2013
Company News

FDA accepts Epanova NDA

...acid (EPA) and docosahexaenoic acid (DHA). AstraZeneca gained the product through its July acquisition of Omthera Pharmaceuticals Inc....
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

...NASDAQ:PETX) 6/27/13 $39.7 62% 13% 49% Portola Pharmaceuticals Inc. (NASDAQ:PTLA) 5/22/13 $140.4 60% 11% 49% Omthera Pharmaceuticals Inc....
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

...the pharma's third significant deal in as many months, following the acquisitions of hypertriglyceridemia company Omthera Pharmaceuticals Inc....
Items per page:
1 - 10 of 54
BioCentury | Feb 18, 2016
Financial News

Corvidia raises $26M, licenses cardio candidate

...hopes to have results about a year after the trial starts. Davidson was CMO of Omthera Pharmaceuticals Inc....
BioCentury | May 19, 2014
Company News

Ligand, AstraZeneca deal

...Ligand partnered with AstraZeneca's Omthera Pharmaceuticals Inc. subsidiary to develop products to treat dyslipidemia, including hypertriglyceridemia. The products...
...for milestone payments of up to $44.5 million, as well as tiered, mid-to-high, single-digit royalties. Omthera...
...molecule into an inactive prodrug to be activated by enzymes in the liver. AZ acquired Omthera...
BioCentury | May 12, 2014
Strategy

Build up to break up

...guidance in last week's review. AZ gained the product in its July 2013 acquisition of Omthera Pharmaceuticals Inc....
BioCentury | May 12, 2014
Clinical News

Epanova regulatory update

...AZ gained the product through its July acquisition of Omthera Pharmaceuticals Inc. (see BioCentury, July 22, 2013). Omthera...
BioCentury | May 7, 2014
Company News

FDA approves AZ's Epanova for severe hypertriglyceridemia

...has not yet set a price. AZ gained Epanova through its acquisition last year of Omthera Pharmaceuticals Inc....
BioCentury | Mar 24, 2014
Company News

Novira management update

...Radnor, Pa. Business: Infectious Hired: Christian Schade as CEO, formerly EVP and CFO of Omthera Pharmaceuticals Inc....
BioCentury | Sep 23, 2013
Clinical News

Epanova regulatory update

...DHA). AstraZeneca gained the product through its July acquisition of Omthera Pharmaceuticals Inc. (see BioCentury, July 22). Omthera...
BioCentury | Sep 19, 2013
Company News

FDA accepts Epanova NDA

...acid (EPA) and docosahexaenoic acid (DHA). AstraZeneca gained the product through its July acquisition of Omthera Pharmaceuticals Inc....
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

...NASDAQ:PETX) 6/27/13 $39.7 62% 13% 49% Portola Pharmaceuticals Inc. (NASDAQ:PTLA) 5/22/13 $140.4 60% 11% 49% Omthera Pharmaceuticals Inc....
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

...the pharma's third significant deal in as many months, following the acquisitions of hypertriglyceridemia company Omthera Pharmaceuticals Inc....
Items per page:
1 - 10 of 54